• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

BCR-ABL 招募 GRB2 在慢性髓性白血病中的结构基础。

The structural basis of BCR-ABL recruitment of GRB2 in chronic myelogenous leukemia.

机构信息

Cancer Innovation Laboratory, National Cancer Institute, Frederick, Maryland.

Computational Structural Biology Section, Frederick National Laboratory for Cancer Research, Frederick, Maryland.

出版信息

Biophys J. 2022 Jun 21;121(12):2251-2265. doi: 10.1016/j.bpj.2022.05.030. Epub 2022 May 31.

DOI:10.1016/j.bpj.2022.05.030
PMID:35651316
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9279350/
Abstract

BCR-ABL drives chronic myeloid leukemia (CML). BCR binding to GRB2 transduces signaling via the Ras/MAPK pathway. Despite considerable data confirming the binding, molecular-level understanding of exactly how the two proteins interact, and, especially, what are the determinants of the specificity of the SH2 domain-phosphorylated BCR (pBCR) recognition are still open questions. Yet, this is vastly important for understanding binding selectivity, and for predicting the phosphorylated receptors, or peptides, that are likely to bind. Here, we uncover these determinants and ascertain to what extent they relate to the affinity of the interaction. Toward this end, we modeled the complexes of the pBCR and SH2 and other pY/Y-peptide-SH2 complexes and compared their specificity and affinity. We observed that pBCR's FpYVNV motif is favorable and specific to SH2, similar to pEGFR, but not other complexes. SH2 contains two binding pockets: pY-binding recognition pocket triggers binding, and the specificity pocket whose interaction is governed by N179 in pBCR and W121 in SH2. Our proposed motif with optimal affinity to SH2 is E/D-pY-E/V-N-I/L. Collectively, we provide the structural basis of BCR-ABL recruitment of GRB2, outline its specificity hallmarks, and delineate a blueprint for prediction of BCR-binding scaffolds and for therapeutic peptide design.

摘要

BCR-ABL 驱动慢性髓性白血病 (CML)。BCR 与 GRB2 的结合通过 Ras/MAPK 途径转导信号。尽管有大量数据证实了这种结合,但对于这两种蛋白质的确切相互作用方式,尤其是 SH2 结构域磷酸化 BCR (pBCR) 识别的特异性决定因素,分子水平的理解仍然存在疑问。然而,这对于理解结合选择性和预测可能结合的磷酸化受体或肽至关重要。在这里,我们揭示了这些决定因素,并确定它们在多大程度上与相互作用的亲和力有关。为此,我们对 pBCR 和 SH2 以及其他 pY/Y-肽-SH2 复合物的复合物进行了建模,并比较了它们的特异性和亲和力。我们观察到,pBCR 的 FpYVNV 基序对 SH2 具有有利和特异性,类似于 pEGFR,但与其他复合物不同。SH2 包含两个结合口袋:pY 结合识别口袋触发结合,特异性口袋的相互作用由 pBCR 中的 N179 和 SH2 中的 W121 控制。我们提出的与 SH2 具有最佳亲和力的基序是 E/D-pY-E/V-N-I/L。总的来说,我们提供了 BCR-ABL 募集 GRB2 的结构基础,概述了其特异性特征,并为 BCR 结合支架的预测和治疗性肽设计描绘了蓝图。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed3/9279350/9299476b5386/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed3/9279350/faeecadbbd5b/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed3/9279350/567b64a0ae0d/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed3/9279350/85f10fdc13c9/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed3/9279350/a96f947c6671/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed3/9279350/09023a181bd6/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed3/9279350/3c97e33cec82/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed3/9279350/d6467c22baee/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed3/9279350/38bec8485349/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed3/9279350/9299476b5386/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed3/9279350/faeecadbbd5b/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed3/9279350/567b64a0ae0d/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed3/9279350/85f10fdc13c9/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed3/9279350/a96f947c6671/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed3/9279350/09023a181bd6/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed3/9279350/3c97e33cec82/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed3/9279350/d6467c22baee/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed3/9279350/38bec8485349/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed3/9279350/9299476b5386/gr9.jpg

相似文献

1
The structural basis of BCR-ABL recruitment of GRB2 in chronic myelogenous leukemia.BCR-ABL 招募 GRB2 在慢性髓性白血病中的结构基础。
Biophys J. 2022 Jun 21;121(12):2251-2265. doi: 10.1016/j.bpj.2022.05.030. Epub 2022 May 31.
2
Growth of chronic myeloid leukemia cells is inhibited by infection with Ad-SH2-HA adenovirus that disrupts Grb2-Bcr-Abl complexes.Ad-SH2-HA 腺病毒感染可抑制慢性髓性白血病细胞的生长,该病毒破坏 Grb2-Bcr-Abl 复合物。
Oncol Rep. 2011 May;25(5):1381-8. doi: 10.3892/or.2011.1197. Epub 2011 Mar 1.
3
The SH2-containing adapter protein GRB10 interacts with BCR-ABL.含SH2结构域的衔接蛋白GRB10与BCR-ABL相互作用。
Oncogene. 1998 Aug 27;17(8):941-8. doi: 10.1038/sj.onc.1202024.
4
The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase.Grb2结合位点是Bcr/Abl酪氨酸激酶在小鼠中诱导慢性髓性白血病样疾病所必需的。
Blood. 2000 Jul 15;96(2):664-70.
5
Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.Bcr-Abl癌蛋白直接与Ras信号通路的激活剂结合。
EMBO J. 1994 Feb 15;13(4):764-73. doi: 10.1002/j.1460-2075.1994.tb06319.x.
6
Purification and molecular cloning of SH2- and SH3-containing inositol polyphosphate-5-phosphatase, which is involved in the signaling pathway of granulocyte-macrophage colony-stimulating factor, erythropoietin, and Bcr-Abl.含SH2和SH3结构域的肌醇多磷酸-5-磷酸酶的纯化及分子克隆,该酶参与粒细胞-巨噬细胞集落刺激因子、促红细胞生成素和Bcr-Abl的信号通路。
Blood. 1997 Apr 15;89(8):2745-56.
7
Targeting BCR tyrosine177 site with novel SH2-DED causes selective leukemia cell death in vitro and in vivo.针对 BCR 酪氨酸 177 位点的新型 SH2-DED 在体外和体内引起选择性白血病细胞死亡。
Int J Biochem Cell Biol. 2012 Jun;44(6):861-8. doi: 10.1016/j.biocel.2012.02.008. Epub 2012 Feb 13.
8
Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes.破坏Grb2 - Sos复合物的肽可抑制慢性粒细胞白血病母细胞增殖。
Blood. 2001 Sep 15;98(6):1773-81. doi: 10.1182/blood.v98.6.1773.
9
The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL.嵌合泛素连接酶 SH2-U 盒通过靶向天然和 T315I 突变 BCR-ABL 抑制伊马替尼敏感和耐药 CML 的生长。
Sci Rep. 2016 Jun 22;6:28352. doi: 10.1038/srep28352.
10
NHD2-15, a novel antagonist of Growth Factor Receptor-Bound Protein-2 (GRB2), inhibits leukemic proliferation.NHD2-15,一种生长因子受体结合蛋白-2(GRB2)的新型拮抗剂,可抑制白血病增殖。
PLoS One. 2020 Aug 11;15(8):e0236839. doi: 10.1371/journal.pone.0236839. eCollection 2020.

引用本文的文献

1
Distinct Allosteric Networks in CDK4 and CDK6 in the Cell Cycle and in Drug Resistance.细胞周期及耐药性中CDK4和CDK6的不同变构网络
J Mol Biol. 2025 Mar 31:169121. doi: 10.1016/j.jmb.2025.169121.
2
Distinct allosteric networks in CDK4 and CDK6 in the cell cycle and in drug resistance.细胞周期及耐药性中CDK4和CDK6内不同的变构网络
bioRxiv. 2025 Mar 6:2025.02.28.640857. doi: 10.1101/2025.02.28.640857.
3
Allostery in Disease: Anticancer Drugs, Pockets, and the Tumor Heterogeneity Challenge.疾病中的变构作用:抗癌药物、靶点口袋与肿瘤异质性挑战

本文引用的文献

1
Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance.Abl 激酶的突变改变了药物结合动力学,提示了伊马替尼耐药的新机制。
Proc Natl Acad Sci U S A. 2021 Nov 16;118(46). doi: 10.1073/pnas.2111451118.
2
Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia-From Molecular Mechanisms to Clinical Relevance.慢性髓性白血病中对酪氨酸激酶抑制剂的耐药性——从分子机制到临床相关性
Cancers (Basel). 2021 Sep 26;13(19):4820. doi: 10.3390/cancers13194820.
3
Synthesis and structural characterization of a monocarboxylic inhibitor for GRB2 SH2 domain.
J Mol Biol. 2025 Feb 26:169050. doi: 10.1016/j.jmb.2025.169050.
4
Proliferation Inhibited by Genipin in Human Leukemia K562 Cells: Involvement of Uncoupling Protein 2 in Mitochondrial Damage.京尼平对人白血病K562细胞增殖的抑制作用:解偶联蛋白2参与线粒体损伤
World J Oncol. 2025 Feb;16(1):83-94. doi: 10.14740/wjon1975. Epub 2024 Dec 31.
5
Allosteric modulation of NF1 GAP: Differential distributions of catalytically competent populations in loss-of-function and gain-of-function mutants.神经纤维瘤蛋白1(NF1)GAP的变构调节:功能丧失和功能获得突变体中具有催化活性群体的差异分布。
Protein Sci. 2025 Feb;34(2):e70042. doi: 10.1002/pro.70042.
6
mTOR Variants Activation Discovers PI3K-like Cryptic Pocket, Expanding Allosteric, Mutant-Selective Inhibitor Designs.mTOR变体激活揭示了PI3K样隐蔽口袋,扩展了变构、突变体选择性抑制剂设计。
J Chem Inf Model. 2025 Jan 27;65(2):966-980. doi: 10.1021/acs.jcim.4c02022. Epub 2025 Jan 10.
7
Capturing Autoinhibited PDK1 Reveals the Linker's Regulatory Role, Informing Innovative Inhibitor Design.捕获自动抑制的 PDK1 揭示了接头的调节作用,为创新抑制剂的设计提供了信息。
J Chem Inf Model. 2024 Oct 14;64(19):7709-7724. doi: 10.1021/acs.jcim.4c01392. Epub 2024 Sep 30.
8
GRB2: A dynamic adaptor protein orchestrating cellular signaling in health and disease.GRB2:一种在健康与疾病中协调细胞信号传导的动态衔接蛋白。
Biochem Biophys Rep. 2024 Jul 29;39:101803. doi: 10.1016/j.bbrep.2024.101803. eCollection 2024 Sep.
9
CDK2 and CDK4: Cell Cycle Functions Evolve Distinct, Catalysis-Competent Conformations, Offering Drug Targets.细胞周期蛋白依赖性激酶2和4:细胞周期功能演变为独特的、具有催化活性的构象,提供药物靶点。
JACS Au. 2024 May 14;4(5):1911-1927. doi: 10.1021/jacsau.4c00138. eCollection 2024 May 27.
10
Slower CDK4 and faster CDK2 activation in the cell cycle.细胞周期中 CDK4 激活较慢,而 CDK2 激活较快。
Structure. 2024 Aug 8;32(8):1269-1280.e2. doi: 10.1016/j.str.2024.04.012. Epub 2024 May 3.
GRB2 SH2 结构域单羧酸抑制剂的合成与结构表征。
Bioorg Med Chem Lett. 2021 Nov 1;51:128354. doi: 10.1016/j.bmcl.2021.128354. Epub 2021 Sep 7.
4
Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.阻断突变型 RAS 致癌信号,特别强调 KRAS。
Pharmacol Res. 2021 Oct;172:105806. doi: 10.1016/j.phrs.2021.105806. Epub 2021 Aug 24.
5
The intramolecular allostery of GRB2 governing its interaction with SOS1 is modulated by phosphotyrosine ligands.GRB2 分子内变构调节其与 SOS1 的相互作用,受磷酸酪氨酸配体的调控。
Biochem J. 2021 Jul 30;478(14):2793-2809. doi: 10.1042/BCJ20210105.
6
The mechanism of activation of monomeric B-Raf V600E.单体B-Raf V600E的激活机制。
Comput Struct Biotechnol J. 2021 Jun 4;19:3349-3363. doi: 10.1016/j.csbj.2021.06.007. eCollection 2021.
7
The mechanism of full activation of tumor suppressor PTEN at the phosphoinositide-enriched membrane.肿瘤抑制因子PTEN在富含磷酸肌醇的膜上完全激活的机制。
iScience. 2021 Apr 17;24(5):102438. doi: 10.1016/j.isci.2021.102438. eCollection 2021 May 21.
8
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1 and BCR-ABL1.克唑替尼作为一种ABL1抑制剂,兼具ATP结合和变构抑制作用,对天然BCR-ABL1及其耐药和复合突变体BCR-ABL1均有活性。
Ann Hematol. 2021 Aug;100(8):2023-2029. doi: 10.1007/s00277-020-04357-z. Epub 2021 Jun 10.
9
Accessory proteins of the RAS-MAPK pathway: moving from the side line to the front line.RAS-MAPK 通路的辅助蛋白:从侧线走向前线。
Commun Biol. 2021 Jun 8;4(1):696. doi: 10.1038/s42003-021-02149-3.
10
Strategic Design of Catalytic Lysine-Targeting Reversible Covalent BCR-ABL Inhibitors*.催化赖氨酸靶向可逆共价 BCR-ABL 抑制剂的策略设计*。
Angew Chem Int Ed Engl. 2021 Jul 26;60(31):17131-17137. doi: 10.1002/anie.202105383. Epub 2021 Jun 24.